{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:43:17Z","timestamp":1791499397125,"version":"4.3.4"},"reference-count":7,"publisher":"S. Karger AG","issue":"3","license":[{"start":{"date-parts":[[2019,12,3]],"date-time":"2019-12-03T00:00:00Z","timestamp":1575331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2019,12,3]],"date-time":"2019-12-03T00:00:00Z","timestamp":1575331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncology"],"published-print":{"date-parts":[[2020]]},"abstract":"<jats:p>Retrospective case studies in various cancers have shown clinical benefit from chemotherapy following PD-1 inhibitor progression. We asked whether we see a similar clinical benefit with chemotherapy following PD-1 inhibitor progression in metastatic melanoma. We performed a retrospective study in patients with metastatic melanoma, who had received PD-1 inhibitor-based treatments, subsequently progressed, and eventually received chemotherapy. We identified 25 patients (median age 58 years; range 31\u201377 years; 13 females). Most patients had cutaneous melanoma (72%), were &lt;i&gt;BRAFV600E&lt;\/i&gt;-negative (75%), and received single-agent temozolomide (84%). At a median follow-up of 21.0 months (range: 4.1\u2013154.2 months), 2 patients had durable response to chemotherapy (progression-free survival is 31.9+ and 21.6+ months, respectively), and 1 patient had a partial, short-term response. We conclude that in this poor prognosis group administration of chemotherapy has a 12% response rate that can be durable. Overall, the clinical benefit is not inferior to that of PD-1 inhibitor-based treatments.<\/jats:p>","DOI":"10.1159\/000504578","type":"journal-article","created":{"date-parts":[[2019,12,3]],"date-time":"2019-12-03T22:00:41Z","timestamp":1575410441000},"page":"174-178","source":"Crossref","is-referenced-by-count":13,"title":["Chemotherapy Following PD-1 Inhibitor Blockade in Patients with Unresectable Stage III\/Stage IV Metastatic Melanoma: A Single Academic Institution Experience"],"prefix":"10.1159","volume":"98","author":[{"given":"Georgia\u00a0Sofia","family":"Karachaliou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatih","family":"Ayvali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frances\u00a0A.","family":"Collichio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carrie\u00a0B.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia","family":"Ivanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David\u00a0W.","family":"Ollila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stergios\u00a0J.","family":"Moschos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2019,12,3]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2017.43"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.06.028"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2017.07.034"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0637-6"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2015.11.024"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/1672176"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.e21588"}],"container-title":["Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/504578","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/504578","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T16:12:23Z","timestamp":1745424743000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000504578"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,3]]},"references-count":7,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,2,26]]},"published-print":{"date-parts":[[2020,2,26]]}},"URL":"https:\/\/doi.org\/10.1159\/000504578","archive":["Portico"],"relation":{},"ISSN":["0030-2414","1423-0232"],"issn-type":[{"value":"0030-2414","type":"print"},{"value":"1423-0232","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,3]]}}}